Real World Evidence Market Poised to Double by 2031

The sector's growth is largely fueled by the transition toward value-based care and an increasing reliance on data generated outside traditional clinical trials. Regulators are mirroring this trend; FDA data shows submissions containing real-world evidence more than doubled between 2023 and 2025. Simultaneously, Europe is bolstering its infrastructure through the EMA’s DARWIN EU network, which now aggregates data from approximately 250 million patients across 18 countries.

Technological advancement remains the primary catalyst for this shift, with the industry pivoting toward AI-driven, privacy-preserving evidence generation. While pharmaceutical companies currently lead in adoption, medtech firms are emerging as the fastest-growing end-user segment. These manufacturers are increasingly utilizing real-world data to demonstrate device safety and effectiveness throughout the product lifecycle. North America currently dominates the landscape, holding a 58.3% market share, supported by a mature regulatory environment and the widespread availability of electronic health records and insurance claims data.